|
1
|
Morgan E, Arnold M, Gini A, Lorenzoni V,
Cabasag CJ, Laversanne M, Vignat J, Ferlay J, Murphy N and Bray F:
Global burden of colorectal cancer in 2020 and 2040: Incidence and
mortality estimates from GLOBOCAN. Gut. 72:338–344. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020:
GLOBOCAN Estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Krul MF, Elferink MAG, Kok NFM, Dekker E,
Lansdorp-Vogelaar I, Meijer GA, Nagtegaal ID, Breekveldt ECH, Ruers
TJM, van Leerdam ME and Kuhlmann KFD: Initial impact of national
CRC screening on incidence and advanced colorectal cancer. Clin
Gastroenterol Hepatol. 21:797–807. 2023. View Article : Google Scholar
|
|
4
|
Wele P, Wu X and Shi H: Sex-dependent
differences in colorectal cancer: With a focus on obesity. Cells.
11:36882022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barkley D, Moncada R, Pour M, Liberman DA,
Dryg I, Werba G, Wang W, Baron M, Rao A, Xia B, et al: Cancer cell
states recur across tumor types and form specific interactions with
the tumor microenvironment. Nat Genet. 54:1192–1201. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Elhanani O, Ben-Uri R and Keren L: Spatial
profiling technologies illuminate the tumor microenvironment.
Cancer Cell. 41:404–420. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Luo H, Xia X, Huang LB, An H, Cao M, Kim
GD, Chen HN, Zhang WH, Shu Y, Kong X, et al: Pan-cancer single-cell
analysis reveals the heterogeneity and plasticity of
cancer-associated fibroblasts in the tumor microenvironment. Nat
Commun. 13:66192022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu W, Wu Y, Liu W, Anwaier A, Tian X, Su
J, Huang H, Wei G, Qu Y, Zhang H and Ye D: Tumor-associated
macrophage-derived chemokine CCL5 facilitates the progression and
immunosuppressive tumor microenvironment of clear cell renal cell
carcinoma. Int J Biol Sci. 18:4884–4900. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen D, Zhang X, Li Z and Zhu B: Metabolic
regulatory crosstalk between tumor microenvironment and
tumor-associated macrophages. Theranostics. 11:1016–1030. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Christofides A, Strauss L, Yeo A, Cao C,
Charest A and Boussiotis VA: The complex role of tumor-infiltrating
macrophages. Nat Immunol. 23:1148–1156. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mantovani A, Allavena P, Marchesi F and
Garlanda C: Macrophages as tools and targets in cancer therapy. Nat
Rev Drug Discov. 21:799–820. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pan Y, Yu Y, Wang X and Zhang T:
Tumor-associated macrophages in tumor immunity. Front Immunol.
11:5830842020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cassetta L and Pollard JW: A timeline of
tumour-associated macrophage biology. Nat Rev Cancer. 23:238–257.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Boutilier AJ and Elsawa SF: Macrophage
polarization states in the tumor microenvironment. Int J Mol Sci.
22:69952021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang H, Yung MMH, Ngan HYS, Chan KKL and
Chan DW: The impact of the tumor microenvironment on macrophage
polarization in cancer metastatic progression. Int J Mol Sci.
22:65602021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hwang I, Kim JW, Ylaya K, Chung EJ, Kitano
H, Perry C, Hanaoka J, Fukuoka J, Chung JY and Hewitt SM:
Tumor-associated macrophage, angiogenesis and lymphangiogenesis
markers predict prognosis of non-small cell lung cancer patients. J
Transl Med. 18:4432020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li H, Luo F, Jiang X, Zhang W, Xiang T,
Pan Q, Cai L, Zhao J, Weng D, Li Y, et al: CircITGB6 promotes
ovarian cancer cisplatin resistance by resetting tumor-associated
macrophage polarization toward the M2 phenotype. J Immunother
Cancer. 10:e0040292022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ding CB, Yu WN, Feng JH and Luo JM:
Structure and function of Gab2 and its role in cancer (Review). Mol
Med Rep. 12:4007–4014. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gong R, Li H, Liu Y, Wang Y, Ge L, Shi L,
Wu G, Lyu J, Gu H and He L: Gab2 promotes acute myeloid leukemia
growth and migration through the SHP2-Erk-CREB signaling pathway. J
Leukoc Biol. 112:669–677. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Spohr C, Poggio T, Andrieux G, Schönberger
K, Cabezas-Wallscheid N, Boerries M, Halbach S, Illert AL and
Brummer T: Gab2 deficiency prevents Flt3-ITD driven acute myeloid
leukemia in vivo. Leukemia. 36:970–982. 2022. View Article : Google Scholar :
|
|
21
|
Zhang P, Chen Y, Gong M, Zhuang Z, Wang Y,
Mu L, Wang T, Pan J, Liu Y, Xu J, et al: Gab2 ablation reverses the
stemness of HER2-overexpressing breast cancer cells. Cell Physiol
Biochem. 50:52–65. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Davis SJ, Sheppard KE, Anglesio MS, George
J, Traficante N, Fereday S, Intermaggio MP, Menon U, Gentry-Maharaj
A, Lubinski J, et al: Enhanced GAB2 expression is associated with
improved survival in high-grade serous ovarian cancer and
sensitivity to PI3K inhibition. Mol Cancer Ther. 14:1495–1503.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Duckworth C, Zhang L, Carroll SL, Ethier
SP and Cheung HW: Overexpression of GAB2 in ovarian cancer cells
promotes tumor growth and angiogenesis by upregulating chemokine
expression. Oncogene. 35:4036–4047. 2016. View Article : Google Scholar :
|
|
24
|
Hu X, He B, Zhou L, Xie H and Zheng S:
Expression pattern and clinical significance of Gab2 protein in
hepatocellular carcinoma. Clin Lab. 62:1087–1092. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu R, Sun Y, Chen S, Hong Y and Lu Z:
FOXD3 and GAB2 as a pair of rivals antagonistically control
hepatocellular carcinogenesis. FEBS J. 289:4536–4548. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ding C, Luo J, Yu W, Gao S, Yang L, Chen C
and Feng J: Gab2 is a novel prognostic factor for colorectal cancer
patients. Int J Clin Exp Pathol. 8:2779–2786. 2015.PubMed/NCBI
|
|
27
|
Horst B, Gruvberger-Saal SK, Hopkins BD,
Bordone L, Yang Y, Chernoff KA, Uzoma I, Schwipper V, Liebau J,
Nowak NJ, et al: Gab2-mediated signaling promotes melanoma
metastasis. Am J Pathol. 174:1524–1533. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
29
|
Adams SJ, Aydin IT and Celebi JT: GAB2-a
scaffolding protein in cancer. Mol Cancer Res. 10:1265–1270. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ding C, Luo J, Li L, Li S, Yang L, Pan H,
Liu Q, Qin H, Chen C and Feng J: Gab2 facilitates
epithelial-to-mesenchymal transition via the MEK/ERK/MMP signaling
in colorectal cancer. J Exp Clin Cancer Res. 35:52016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ding C, Luo J, Fan X, Li L, Li S, Wen K,
Feng J and Wu G: Elevated Gab2 induces tumor growth and
angiogenesis in colorectal cancer through upregulating VEGF levels.
J Exp Clin Cancer Res. 36:562017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu K, Lin K, Li X, Yuan X, Xu P, Ni P and
Xu D: Redefining tumor-associated macrophage subpopulations and
functions in the tumor microenvironment. Front Immunol.
11:17312020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guo X, Li T, Xu Y, Xu X, Zhu Z, Zhang Y,
Xu J, Xu K, Cheng H, Zhang X and Ke Y: Increased levels of Gab1 and
Gab2 adaptor proteins skew interleukin-4 (IL-4) signaling toward M2
macrophage-driven pulmonary fibrosis in mice. J Biol Chem.
292:14003–14015. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheng Y, Zhu Y, Xu J, Yang M, Chen P, Xu
W, Zhao J, Geng L and Gong S: PKN2 in colon cancer cells inhibits
M2 phenotype polarization of tumor-associated macrophages via
regulating DUSP6-Erk1/2 pathway. Mol Cancer. 17:132018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gao J, Liang Y and Wang L: Shaping
polarization of tumor-associated macrophages in cancer
immunotherapy. Front Immunol. 13:8887132022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kashfi K, Kannikal J and Nath N:
Macrophage reprogramming and cancer therapeutics: Role of
iNOS-derived NO. Cells. 10:31942021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang Q and Sioud M: Tumor-associated
macrophage subsets: Shaping polarization and targeting. Int J Mol
Sci. 24:74932023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bingle L, Brown NJ and Lewis CE: The role
of tumour-associated macrophages in tumour progression:
Implications for new anticancer therapies. J Pathol. 196:254–265.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang X, Yuwen TJ, Zhong Y, Li ZG and Wang
XY: A new method for predicting the prognosis of colorectal cancer
patients through a combination of multiple tumor-associated
macrophage markers at the invasive front. Heliyon. 9:e132112023.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shen T, Liu JL, Wang CY, Rixiati Y, Li S,
Cai LD, Zhao YY and Li JM: Targeting erbin in B cells for therapy
of lung metastasis of colorectal cancer. Signal Transduct Target
Ther. 6:1152021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hou J, Zhang Y and Zhu Z: Gene
heterogeneity in metastasis of colorectal cancer to the lung. Semin
Cell Dev Biol. 64:58–64. 2017. View Article : Google Scholar
|
|
42
|
Malki A, ElRuz RA, Gupta I, Allouch A,
Vranic S and Al Moustafa AE: Molecular mechanisms of colon cancer
progression and metastasis: Recent insights and advancements. Int J
Mol Sci. 22:1302020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ye Q, Cai W, Zheng Y, Evers BM and She QB:
ERK and AKT signaling cooperate to translationally regulate
survivin expression for metastatic progression of colorectal
cancer. Oncogene. 33:1828–1839. 2014. View Article : Google Scholar :
|
|
44
|
Hijazi M, Casado P, Akhtar N,
Alvarez-Teijeiro S, Rajeeve V and Cutillas PR: eEF2K activity
determines synergy to cotreatment of cancer cells with PI3K and MEK
inhibitors. Mol Cell Proteomics. 21:1002402022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cheng J, Zhong Y, Chen S, Sun Y, Huang L,
Kang Y, Chen B, Chen G, Wang F, Tian Y, et al: Gab2 mediates
hepatocellular carcinogenesis by integrating multiple signaling
pathways. FASEB J. 31:5530–5542. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang Y, Sheng Q, Spillman MA, Behbakht K
and Gu H: Gab2 regulates the migratory behaviors and E-cadherin
expression via activation of the PI3K pathway in ovarian cancer
cells. Oncogene. 31:2512–2520. 2012. View Article : Google Scholar :
|
